Terms: = Breast cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Prognosis
113 results:
1. Impact of kras mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract] [Full Text] [Related]
2. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract] [Full Text] [Related]
3. Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy.
Geerinckx B; Teuwen LA; Foo T; Vandamme T; Smith A; Peeters M; Price T
Expert Rev Anticancer Ther; 2023; 23(12):1237-1249. PubMed ID: 37842857
[TBL] [Abstract] [Full Text] [Related]
4. Mutation Profile via Next-Generation Sequencing in Patients with Colorectal Adenocarcinoma and Its Clinicopathological Correlation.
Osman S; Kahraman Çetin N; Erdoğdu İH; Meteoğlu İ
Turk J Gastroenterol; 2023 Nov; 34(11):1124-1133. PubMed ID: 37737217
[TBL] [Abstract] [Full Text] [Related]
5. Adverse Crosstalk between Extracellular Matrix Remodeling and Ferroptosis in Basal breast cancer.
Desterke C; Cosialls E; Xiang Y; Elhage R; Duruel C; Chang Y; Hamaï A
Cells; 2023 Aug; 12(17):. PubMed ID: 37681908
[TBL] [Abstract] [Full Text] [Related]
6. Synergistic effect of Dactolisib/Lys05 combination on autophagy in A549 cells.
Abdelwahab M; Saeed H; Elnikhely N; Nematalla H
Acta Biochim Pol; 2023 Sep; 70(3):615-622. PubMed ID: 37677845
[TBL] [Abstract] [Full Text] [Related]
7. Mesonephric-like adenocarcinoma of the female genital tract: possible role of kras-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic kras-mutations.
Brambs CE; Horn LC; Hiller R; Krücken I; Braun C; Christmann C; Monecke A; Höhn AK
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15727-15736. PubMed ID: 37668797
[TBL] [Abstract] [Full Text] [Related]
8. A potential tumor marker: Chaperonin containing TCP‑1 controls the development of malignant tumors (Review).
Zheng L; Chen X; Zhang L; Qin N; An J; Zhu J; Jin H; Tuo B
Int J Oncol; 2023 Sep; 63(3):. PubMed ID: 37539774
[TBL] [Abstract] [Full Text] [Related]
9. PDE4DIP contributes to colorectal cancer growth and chemoresistance through modulation of the NF1/RAS signaling axis.
Pan R; Dai J; Liang W; Wang H; Ye L; Ye S; Lin Z; Huang S; Xiong Y; Zhang L; Lu L; Wang O; Shen X; Liao W; Lu X
Cell Death Dis; 2023 Jun; 14(6):373. PubMed ID: 37355626
[TBL] [Abstract] [Full Text] [Related]
10. High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients.
Morrow E; Pennel K; Hatthakarnkul P; Leslie H; Mallon E; Andersen D; Jamieson N; McMillan D; Roseweir A; Edwards J
Cancer Med; 2023 Jun; 12(12):13225-13240. PubMed ID: 37199043
[TBL] [Abstract] [Full Text] [Related]
11. Synthesis and Characterisation of Fluorescent Novel Pt(II) Cyclometallated Complexes with Anticancer Activity.
McGhie BS; Sakoff J; Gilbert J; Gordon CP; Aldrich-Wright JR
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175756
[TBL] [Abstract] [Full Text] [Related]
12. Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal cancer prognosis.
Guo L; Wang Y; Yang W; Wang C; Guo T; Yang J; Shao Z; Cai G; Cai S; Zhang L; Hu X; Xu Y
Gastroenterology; 2023 Aug; 165(2):414-428.e7. PubMed ID: 37146911
[TBL] [Abstract] [Full Text] [Related]
13. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
[TBL] [Abstract] [Full Text] [Related]
14. Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study.
Myint KZY; Shimabuku M; Horio R; Kaneda M; Shimizu Y; Taguchi J
Cancer Treat Res Commun; 2023; 35():100701. PubMed ID: 37094468
[TBL] [Abstract] [Full Text] [Related]
15. Molecular Pathology of Micropapillary Carcinomas: Is Characteristic Morphology Related to Molecular Mechanisms?
Sagnak Yilmaz Z; Sarioglu S
Appl Immunohistochem Mol Morphol; 2023 May-Jun 01; 31(5):267-277. PubMed ID: 37036419
[TBL] [Abstract] [Full Text] [Related]
16. The Relevance of Common K-RAS Gene Mutations and K-RAS mRNA Expression with Clinicopathological Findings and Survival in breast cancer.
Kamian S; Ashoori H; Vahidian F; Davoudi S
Asian Pac J Cancer Prev; 2023 Mar; 24(3):909-914. PubMed ID: 36974544
[TBL] [Abstract] [Full Text] [Related]
17. Identification and validation of eight estrogen-related genes for predicting prognosis of papillary thyroid cancer.
Zeng Y; Ma W; Li L; Zhuang G; Luo G; Zhou H; Hao W; Liu Y; Guo F; Tian M; Ruan X; Gao M; Zheng X
Aging (Albany NY); 2023 Mar; 15(5):1668-1684. PubMed ID: 36917092
[TBL] [Abstract] [Full Text] [Related]
18. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract] [Full Text] [Related]
19. Mammary mucinous cystadenocarcinoma with long-term follow-up: molecular information and literature review.
Lei T; Shi YQ; Chen TB
Diagn Pathol; 2023 Feb; 18(1):13. PubMed ID: 36737820
[TBL] [Abstract] [Full Text] [Related]
20. prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
Bridgewater J; Jiao X; Parimi M; Flach C; Stratford J; Kamburov A; Schmitz AA; Zong J; Reeves JA; Keating K; Bruno A; Fellous M; Pereira MB; Bazhenova L
Cancer Treat Res Commun; 2022; 33():100623. PubMed ID: 36041373
[TBL] [Abstract] [Full Text] [Related]
[Next]
